Portfolio company
Xgenera
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Xgenera develops a multi-cancer early detection blood test to help clinicians and patients identify multiple cancer types at their earliest stages.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Adela
The company develops blood-based genomic tests for early cancer detection and minimal residual disease monitoring for healthcare providers and biopharmaceutical partners.
MetaSight
MetaSight Diagnostics develops multi-omics liquid biopsy tests for the early detection of chronic and acute diseases for healthcare providers and patients.
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
Single molecule diagnostics
This company develops prenatal screening and oncology liquid biopsy tests for clinicians to identify genetic risks and monitor cancer treatments in patients.
Flomics
Flomics develops liquid biopsy blood tests and a bioinformatics platform for early cancer detection in clinical and research settings.
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
Elphogene
This biotechnology company develops a molecular liquid biopsy test to monitor cancer progression and treatment efficacy for oncology patients and healthcare professionals.
Predicta
Predicta develops blood-based molecular diagnostic tests that provide genomic and immune insights for clinicians to guide treatment for patients with blood cancers.